trokendi xr now approved for migraine treatment

Other Indications —
Trokendi XR® for
Certain Types of Epilepsy

Trokendi XR is a once-daily topiramate

In addition to migraine prevention, Trokendi XR is indicated as initial monotherapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures and as adjunctive therapy in patients 6 years of age and older with partial onset, primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome.

In a conversion study, 93.4% of patients with epilepsy who had been taking a stable dose of immediate-release topiramate for a minimum of 1 month prior to study entry preferred Trokendi XR1

topiramate reviews and preference for trokendi xr

Converting your patients to once-daily Trokendi XR is easy1

Example of same-day conversion for patients taking twice-daily Topamax1-3†

Trokendi XR vs. Topamax switching treatments

Tablets and capsule shown are not actual size.

†Recommended dose of Trokendi XR as adjunctive therapy in adults with partial onset seizures is 200 mg/day.

Dosage and administration for new patient starts2

trokendi xr dosing table